Stage 4 pancreatic cancer survival improves by a 4-drug chemotherapy regimen

Written By : Isra Zaman

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2023-01-23 04:00 GMT | Update On 2023-01-23 04:00 GMT

A four-drug chemotherapy regimen provided longer overall survival than a two-drug combination in a Phase 3 clinical trial for metastatic pancreatic ductal adenocarcinoma. The study is believed to be the first metastatic pancreatic cancer study in nearly a decade to have a positive endpoint for overall survival.

For the study, 770 patients were randomly assigned to one of two chemotherapy regimens. Patients in the four-drug group had an overall survival of 11.1 months, compared with 9.2 months for those in the two-drug arm.

Progression-free survival also increased with the four-drug therapy - 7.4 months versus 5.6 months with the two-drug regimen. Several side effects, such as diarrhea, nausea and low levels of potassium, were more common in patients taking the four-drug treatment, but anemia and low levels of white blood cells were more common in those taking the two drugs.

The four-drug regimen consisted of liposomal irinotecan, 5-fluorouracil/leucovorin and oxaliplatin - together referred to as NALIRIFOX. The two-drug therapy consisted of nab-paclitaxel and gemcitabine.The clinical trial included patients in more than 25 countries.

Reference:

NAPOLI-3: A Randomized, Open-label Phase 3 Study of Liposomal Irinotecan + 5-fluorouracil/leucovorin + Oxaliplatin (NALIRIFOX) versus Nab-paclitaxel + Gemcitabine in Treatment-naïve Patients with Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC),UN

Full View

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Isra Zaman

Isra Zaman is a Life Science graduate from Daulat Ram College, Delhi University, and a postgraduate in Biotechnology from Amity University. She has a flair for writing, and her roles at Medicaldialogues include that of a Sr. content writer and a medical correspondent. Her news pieces cover recent discoveries and updates from the health and medicine sector. She can be reached at editorial@medicaldialogues.in.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Stage 4 pancreatic cancer survival improves by a 4-drug chemotherapy regimen

Similar News

Caltech Engineers Develop Smart Ingestible Capsule for Real-Time Gut Health Monitoring

New Blood Test May Detect Early Liver Transplant Rejection: Study Suggests

Six in Ten with Type 2 Diabetes Have Fatty Liver: Study Finds

Why Alcohol-Related Liver Disease Are Rising in Women? Study Sheds Light

Clinical Trial Shows Diabetes Drug May Help Treat Liver Inflammation

How Plastic Particles in Food Affect Liver Function: Study Sheds Light

Mediterranean Diet Shows Potential for Easing Irritable Bowel Syndrome: Study

First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan